Eduardo Torres, MD
Family Medicine · Winter Haven, FLNPI 1679553606
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 440 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 21.0% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 440 payments — averaging $21.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Novo Nordisk$786
- AbbVie$692
- Pfizer$605
- Lilly USA, LLC$579
- plus $3K from 33 others
Across 402 payments — averaging $3083.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$744K
- Astrazeneca UK Limited$377K
- AstraZeneca$67K
- Novo Nordisk AS$52K
What the payments were for
- Food & beverage$9,603100%
- Education$470%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$378
- AIRSUPRA$126
- VERQUVO$113
- ENTRESTO$110
- OPSUMIT$109
- VRAYLAR$107
- TRELEGY ELLIPTA$106
- DEXCOM G7 GSS (161)$101
- Symbravo$101
How this compares
$9,650 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $147,691 |
| JardianceEmpagliflozin | 79 | $91,149 |
| MounjaroTirzepatide | 72 | $88,450 |
| RybelsusSemaglutide | 57 | $82,796 |
| EliquisApixaban | 71 | $65,259 |
| MyrbetriqMirabegron | 74 | $59,488 |
| TrulicityDulaglutide | 39 | $58,857 |
| FarxigaDapagliflozin Propanediol | 39 | $50,864 |
| RexultiBrexpiprazole | 21 | $36,112 |
| JanuviaSitagliptin Phosphate | 20 | $27,750 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $24,347 |
| EntrestoSacubitril/Valsartan | 16 | $17,528 |
| XareltoRivaroxaban | 12 | $17,473 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $15,105 |
| SymbicortBudesonide/Formoterol Fumarate | 47 | $14,760 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $786 | $233,400168 claims |
| Lilly USA, LLCMounjaro, Trulicity | $579 | $147,308111 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $247 | $97,79392 claims |
| AstraZenecaFarxiga, Symbicort | $2,026 | $65,62486 claims |
| PfizerEliquis | $605 | $65,25971 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $59,48874 claims |
| MerckJanuvia, Janumet | $455 | $42,85534 claims |
| GSKTrelegy Ellipta, Arexvy, Shingrix | $1,497 | $39,33082 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $105 | $36,11221 claims |
| AbbVieLinzess, Savella, Synthroid | $692 | $23,59956 claims |
| NovartisEntresto | $409 | $17,52816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Winter Haven
- Nathan FalkWinter Haven$79K
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.